Curative approaches of MPN

[Manouche]

JAK2V617F myeloproliferative neoplasm eradication by a novel interferon/arsenic therapy involves PML

« We demonstrate that the IFNα+ATO combination specifically targets the Jak2V617F disease-initiating cells in vivo, with a much higher potency than IFNα alone. These cooperative effects were observed in a wide variety of JAK2V617F-expressing models, including primary hematopoietic progenitors, suggestive of therapeutic relevance. »

« The IFNα+ATO combination had a favorable safety profile in another hematologic malignancy (Kchour et al., 2009), and availability of oral forms of ATO (Zhu et al., 2018) may allow outpatient therapy, paving the way toward eradication of JAK2V617F MPN cells. »

rupress.org/jem/article/218...

[Bigcheat]

Hi Manouche,

Thanks for posting the article. They didn’t give the therapy to any patients, or did they? I wonder how long before clinical trials could start, because it surely looks promising based on the article!

Cheers,

Bigcheat

[Manouche in reply to Bigcheat]

Hi Bigcheat,

I’m not aware about clinical trials with this drugs combination yet, but it’s coming up soon.

« Arsenic trioxide (ATO) has been recognized as a drug for the treatment of various diseases in traditional medicine for more than two thousand years. Although ATO has recently shown excellent efficacy for the treatment of acute promyelocytic leukemia (APL), it could not provide satisfactory outcomes as a single-agent for the management of non-APL leukemia or different solid tumors. Nevertheless, combination treatment strategies, e.g., ATO with other agents, have shown promising results against different diseases. »

pubs.rsc.org/en/content/art...

[hunter5582]

Very interesting. Will be looking to learn more about this potential treatment option,